The (mis)use of treatment switching adjustment methods in health technology assessment – *busting some myths!*

**ISPOR Barcelona, 2018**

Dr Nicholas Latimer (*n.latimer@sheffield.ac.uk*)
Reader in Health Economics, School of Health and Related Research, University of Sheffield, UK

Nicholas Latimer is funded by a National Institute for Health Research Post-doctoral Fellowship. These slides present independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

---

**Treatment switching**

- 40% of NICE TAs are in cancer
- Treatment switching is an issue in over 55% of oncology technology assessments
  - Adjustment methods can change decisions

<table>
<thead>
<tr>
<th>NICE TA321 Dabrafenib for melanoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>57% switched</td>
</tr>
<tr>
<td>ITT analysis:  OS HR 0.76; ICER £95,225</td>
</tr>
<tr>
<td>Adjustment analysis: OS HR 0.55; ICER £49,019</td>
</tr>
<tr>
<td>Dabrafenib was recommended for use</td>
</tr>
</tbody>
</table>
Treatment switching

• But…
  − <50% TAs include adjustments for switching
  − ≈60% of adjustment analyses rejected

• Reliance on ITT, or upon poor adjustment analyses, has severe consequences
  − Inappropriate recommendations
  − Sub-optimal resource allocation
  − Lost lives, lost QALYs

Why aren’t we using adjustment analyses more?

Low decision-maker confidence in methods
  - Methods make untestable assumptions which may lack face-validity

Poor application of methods
  - Don’t justify use
  - Incorrect application
  - Poor reporting
Addressing some of these issues

Important issues that I won’t cover...

1. **Method selection.** It is not sensible to present analyses using only one adjustment method, without properly describing why other methods are not appropriate.

2. **Reporting.** Analyses should always be comprehensively reported, e.g.
   - What covariates were included and why
   - What was assumed about the durability of the treatment effect
   - Analyses with and without re-censoring
   - What range of weights came out of weighting analyses
   ➔ Work is ongoing on reporting standards for adjustment analyses

Addressing some of these issues

Areas that I will cover...
Areas where methods are being **mis-understood,** or used **sub-optimally:**

1. Enforced use of hazard ratios
2. Assessment of the common treatment effect assumption
3. Unmeasured confounding and missing data
Enforced use of hazard ratios

- Adjustment methods usually used to estimate hazard ratios (HR)
  → Rely upon proportional hazards assumption in survival/economic models
  → Economic models that rely on PH are often unpopular
  → Therefore, adjustment analyses may be unpopular

→ This is not necessary!

Myth-bust #1
Methods do not necessarily produce adjusted HRs

If we do an adjustment analysis it does not mean that we must use HRs in our economic model
Common treatment effect (CTE) assumption

• The RPSFTM relies upon the CTE assumption
• Has been rejected due to its reliance on CTE

• It is impossible to test this assumption **BUT**
→ **Analysis of the CTE assumption has been sub-optimal**

---

1. Sensitivity analysis can (and must) be done
   → e.g. what if switchers got 10/20/50% reduced effect?
   → does it make much difference?

2. Two-stage method provides an estimate of the AF specific to switchers
   → Compare this to the AF from the RPSFTM
     – are the AFs similar?

---

**Myth-bust #2**

We do not have to just accept (or not) the common treatment effect assumption

It is not a case of “we don’t believe the CTE assumption so there’s no point looking at the RPSFTM”

Further investigation is required
Unmeasured confounding and missing data

- IPCW and two-stage (TSE) methods rely upon “no unmeasured confounding” (NUC) assumption
  → Put *everything* in the models
  → Unless *everything* is measured in the trial, don’t believe in these methods

→ This is not necessary and may be wrong
→ Need to consider what constitutes a confounder

1. Why is the data missing? i.e. can it be observed by the clinician?
2. Does the missing variable have an independent causal effect?

Myth-bust #3
IPCW and TSE shouldn’t be thrown out “just” because a potentially important variable is missing.

Further investigation is required – could it be a confounder? Is it independent?
Conclusions

• If we want adjustment methods to be used more we need to use them better
• There are lots of quite simple things that we can do that can increase the likelihood that adjustment analyses will be believed/used